p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy-Reference-Cited by-同舟云学术

p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Published:2019-03-21 Issue:8 Volume:120 Page:797-805
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Oh Hyeon Jeong,Bae Jeong Mo,Wen Xianyu,Jung Seorin,Kim Younghoon,Kim Kyung Ju,Cho Nam-Yun,Kim Jung Ho,Han Sae-Won,Kim Tae-You,Kang Gyeong Hoon

Funder

Seoul National University Hospital

National Research Foundation of Korea

Korea Health Industry Development Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0429-2.pdf

Reference48 articles.

1. O’Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G. & Mayer, R. J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol. 15, 246–250 (1997).

2. Andre, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O. & Achille, E. et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol. 21, 2896–2903 (2003).

3. Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T. & Topham, C. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).

4. Kuebler, J. P., Wieand, H. S., O’Connell, M. J., Smith, R. E., Colangelo, L. H. & Yothers, G. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25, 2198–2204 (2007).

5. Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N. & Song, K. et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 17, 1349–1355 (1999).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p21 Prevents the Exhaustion of CD4+ T Cells Within the Antitumor Immune Response Against Colorectal Cancer;Gastroenterology;2024-02

2. Pan-cancer Analysis Reveals m⁶A Variation and Cell-specific Regulatory Network in Different Cancer Types;2023-12-13

3. Vasopressin Analog [V⁴Q⁵]dDAVP Exerts Cooperative Anticancer Effects in Combination With Low-Dose 5-Fluorouracil on Aggressive Colorectal Cancer Models;World Journal of Oncology;2023-12

4. DYRK2 promotes chemosensitivity via p53‐mediated apoptosis after DNA damage in colorectal cancer;Cancer Science;2023-09-30

5. RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity;International Journal of Oncology;2023-08-31